Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-03463275 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single dose | EXPERIMENTAL | - |
| Multiple dose | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-03463275 | DRUG | Oral single 20 mg dose as two 10mg controlled release tablets |
| Placebo | DRUG | Oral single dose as matching placebo |
Inclusion Criteria: * Healthy male subjects between the ages of 18 and 55 years. * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2, and a total body weight \>50 kg (110 lbs). * Japanese subjects must have four Japanese grandparents who were born in Japan. Exclusion Criteria: * Subjects that are genot...
PF-03463275 is an investigational small molecule being studied for use in healthy volunteers. It is not approved for any disease or condition and is currently in clinical development to evaluate its pharmacokinetics, safety, and tolerability.
PF-03463275 is being developed by Pfizer, Inc. (NYSE: PFE). The company is conducting clinical trials to assess the drug's safety and tolerability in healthy subjects.
PF-03463275 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed.
PF-03463275 has one completed Phase 1 trial, NCT01159626, which studied its pharmacokinetics, safety, and tolerability in healthy male Japanese and Western subjects. The trial enrolled 40 participants and was conducted in the United States.
No alternative names for PF-03463275 have been disclosed. It is identified solely by its code name PF-03463275 in clinical trial records.